Background and aims Despite extensive research on HIV and hepatitis C (HCV) among people who inject drugs
INTRODUCTION
Injection drug use remains a major global health challenge that includes its role in the transmission of blood-borne infections such as HIV and hepatitis C virus (HCV) and their associated morbidity and mortality. In 2007, there were an estimated 16 million people who inject drugs (PWID) world-wide, with Asia and eastern Europe having a comparatively larger injecting population [1] . HIV prevalence among PWID generally ranges from 20 to 40% and HCV from 60 to 80% [2] . Due to the higher per-act transmission probability of HCV compared to HIV when sharing injection paraphernalia [3, 4] , PWID most often have a higher prevalence of HCV than HIV [5] .
While the epidemiology of HCV and HIV infection in PWID has been studied extensively, the large majority focus on men leading to a gap in knowledge on the burden among women and their unique context and risk profile [6, 7] . A review from 2010 found that a third of people who use drugs are women, with 3.8 million women injecting drugs globally [8] . Consequently, scholars and the United Nations Office on Drugs and Crime have called for researchers to distinguish between the different risks and burden of infections among men and women who use drugs [7, 9] .
Injection drug use continues to be a major driver of the HIV epidemic in some regions of India, with an estimated 1.1 million PWID [10] . The Northeast region, near the opium-producing area known as the 'Golden Triangle', has the oldest injection drug use epidemic [11] . Government-and non-government-operated prevention interventions targeting PWID have slowed the epidemic there [12] [13] [14] ; however, the Northeast continues to see a consistently higher HIV prevalence [15] [16] [17] . The Northeast is also home to the vast majority of women who inject drugs in India, with an emerging population of women injecting heroin and pharmaceutical opioids [15, 18, 19] . A previous study among PWID in the Northeast found women more likely to be HIV-infected than men [16] . This is consistent with other contexts in which women are more vulnerable to HIV and other health-related harms because of stigma, violence and riskier sexual and injecting behaviours [19] [20] [21] . Our findings from a previous analysis among PWID in India support this higher vulnerability to HIV infection among women [15] ; in contrast, however, we found that women had lower odds of HCV compared to men [22] . Therefore, our objective is to (1) compare the prevalence of HIV and HCV in women and men who inject drugs and (2) estimate associations between injection and sexual risk correlates and prevalent HIV and HCV infection among women who inject drugs in Northeast India.
METHODS

Study design and population
The study population comprises of PWID across seven cities in Northeast India, a subset of 14 481 PWID across 15 Indian cities recruited as part of the baseline crosssectional assessment of a cluster-randomized trial [23] (ClinicalTrials.gov Identifier: NCT01686750). Cities (state) included in this analysis are: Aizawl and Lunglei (Mizoram), Churachandpur, Imphal, and Moreh (Manipur), Dimapur (Nagaland) and Gangtok (Sikkim). Eligibility criteria included: age ≥ 18 years, informed consent, valid referral coupon and self-reported drug injection in the previous 2 years. A total of 1000 participants per city, except Moreh (n = 457), were recruited using respondent-driven sampling (RDS), a chain-referral strategy [23] [24] [25] [26] [15, 27] .
Statistical analysis
HIV and HCV prevalence estimates were stratified by gender for comparison. City-level HIV and HCV prevalence were calculated with RDS-II weights using network size (i.e. number of PWID seen in the previous 30 days) to compensate for non-random sampling [28] . Population estimates with all cities combined were calculated using a composite weight which accounts for the relative PWID population size in each city derived from state-level data [29] and the RDS-II weight.
Restricting to women, correlates of prevalent HIV and HCV infection were estimated using multi-level logistic regression models with a random intercept for city, thus interpretation of odds ratios is conditional upon city and RDS-II weights as sampling weights. Correlates were considered for inclusion in the multivariable model if significant at a P-value < 0.1 in univariable and retained if significant at a P-value < 0.05 after adjustment, with the exception of age and duration of injection drug use, which were included regardless of significance. Unweighted analyses are shown in the Supporting information [30] . Analyses were performed using RDS Analyst version 1.0 (http://hpmrg.org) and Stata version 13.1 (Stata Corp., College Station, TX, USA).
RESULTS
Among 6457 PWID recruited, 796 (15.9%) were women. Median age among women was 30 years (interquartile range = 25-35) ( Table 1) ; 52.6% were married and more than a quarter were divorced, separated or widowed. Nearly 30% injected only heroin, 42.6% only buprenorphine/pharmaceuticals and 28.0% a combination of drugs. One-third reported sex with another PWID in the prior 6 months, nearly half (47.3%) reported unprotected sex in the previous 6 months and 12.6% had a history of sex work.
Overall HIV prevalence among women was 52.9% [95% confidence interval (CI) = 49.3-6.5%] and HCV prevalence was 22.3% (95% CI = 19.9-24.7%). For comparison, among men HIV prevalence was 17.4% (95% CI = 16.9-17.9%) and HCV prevalence was 30.4% Table 1 Correlates of prevalent HIV infection and hepatitis C infection among 796 women who inject drugs in Northeast India. (95% CI = 31.2-32.0%). There was considerable city-level variability; HIV among women ranged from 10.4 to 74.8% and HCV ranged from 0 to 56.6% (Fig. 1) . HIV in women was higher than HCV in five of the seven cities. In contrast, for men, five of the seven cities had lower HIV than HCV. Unweighted prevalence estimates were generally higher than weighted estimates (Table S2 ). Coinfection among women was 11.0% (95% CI = 8.9-13.1%). Among HIV-infected women, 20.8% were coinfected with HCV; conversely, among those HCV-infected, 49.4% were coinfected with HIV (see Supporting information, Tables  S3 and S4 for estimates by city and for men). Unweighted prevalence estimates by additional subgroups are in Supporting information, Table S6 . In univariable analysis, HIV infection among women was associated with being older, widowed, having children, longer duration of injection drug use, less frequent injection in the previous 6 months, ever sharing a needle/syringe and a higher number of life-time sexual partners (Table 1) . Women who were never married and had ever used opioid agonist therapy were significantly less likely to have HIV. In multivariable analysis, widows were four times as likely to be HIV-infected [adjusted odds ratio (aOR) = 4.03] compared to those currently married; eight or more life-time sexual partners were associated with three times higher odds of HIV compared to those with none (aOR = 3.08). Findings were inconclusive as to whether HCV was associated with HIV and vice versa.
In univariable analysis, HCV infection was associated with being divorced/separated, longer duration of injection drug use, only injecting heroin or a combination of drugs, ever sharing a needle/syringe, harm reduction use, a higher number of life-time sexual partners and a PWID network > 50. In multivariable analysis, increasing duration of injection drug use was associated with 70% higher odds of HCV (aOR = 1.70, per 10 years). Injecting only heroin was associated with 5.6 times higher odds of HCV (aOR = 5.63), and combination drug use had 2.6 times higher odds (aOR = 2.58) compared to injecting only pharmaceuticals opioids. A history of ever sharing needles or syringes was associated with 2.5 times higher odds of HCV (aOR = 2.46), and those with a network of > 50 PWID were 4.2 times more likely to have HCV (aOR = 4.17) compared to those with a network of one to five.
DISCUSSION
Among a sample of women who inject drugs in Northeast India we observed a higher prevalence of HIV than HCV, 53 and 22%, respectively. This pattern of a higher HIV burden than HCV was fairly consistent-within five of the seven cities-and contrasts with what we observed among men in the same region. Among most populations of PWID, HCV prevalence is an order of magnitude higher than HIV [31, 32] . Notably, we found HCV was higher than HIV prevalence among women in two cities-Aizawl Figure 1 Percentage point difference between HIV and hepatitis C virus (HCV) prevalence by gender and Imphal-where HCV prevalence was highest among men. This may reflect differential drug availability (e.g. increased heroin availability in Imphal) and consequently injection patterns among women in these settings.
A previous study in Nagaland and Mizoram among women PWID found a more typical pattern of HIV and HCV prevalence: 24 and 67%, respectively, with women having a higher HIV and HCV burden compared to men [16] . However, this sample of women was small and recruited from drop-in centres, rather than a networkbased strategy, which may be more representative of the underlying population including those not seeking services.
This unusual pattern of HIV and HCV prevalence among women is coupled with contrasting correlates for the two infections. HCV was associated with typical injection-related risk behaviours including sharing needles/syringes, a larger PWID network, longer duration of injection and injecting only heroin or a combination of drugs. Drug types may represent differing injection frequency, preparation or injection environments.
Conversely, HIV was associated primarily with sexual risk factors-high numbers of sexual partners and being widowed. The relationship between HIV and widowhood has been observed among women attending sexually transmitted infection clinics in India [33] . A considerable amount of Indian women's HIV risk comes from heterosexual sex with one partner, generally their husband [34] [35] [36] [37] . The univariable finding of a higher likelihood of HIV with lower frequency of recent injection is due probably to cessation or reduction in use after diagnosis; more than 70% of those HIV-infected were aware of their infection. Our results suggest that sex remains a substantial route of HIV acquisition for women injectors in India, as seen in other contexts [38] [39] [40] [41] . Similarly, a longitudinal study in the United States found that high-risk heterosexual activity but not injection-related factors was associated with HIV seroconversion among women PWID [39] . Our previous analysis of the combined sample of PWID from the Northeast, North and Central regions of India, which consisted largely of men (> 90%), found that no sexual risk factors were associated independently with HIV infection; rather, only injection-related factors were associated with HIV [15] .
Previous research among women PWID has found a significant link between intimate relationships and riskier behaviours. Compared to men who inject, women are more likely to have unprotected sex with a primary partner [21] , more likely to have sexual partners who are also PWID and are more often initiated to drug injection by a sexual partner [8, 42] . Male PWID often report inconsistent condom usage, especially with regular partners [37, [43] [44] [45] [46] [47] . Indeed, in our study, a third of the women reported recent sex with another PWID and almost half had unprotected sex. Sexual networks, relationships and risk behaviours among women differ substantively from men who inject drugs, which has direct consequences for HIV prevention efforts.
Our study has limitations. Cross-sectional data do not allow for establishment of temporality or causality between the factors of interest and prevalent HIV/HCV infection. RDS weighting schemes should provide unbiased population estimates. However, we cannot confirm that the sample or estimates are representative of the underlying population. Double vulnerability stemming from sexual and injection-related factors among women underscores the need for complete availability of the nine-component comprehensive harm reduction package for PWID [48] and tailored delivery of these services with women's specific context and needs in mind. Focusing solely upon injection drug use-related services such as needle/syringe exchange and opioid substitution therapy will probably be inadequate to address HIV in this population. Partner counselling, safe sex education, pre-exposure prophylaxis and other sexual health services should be emphasized and integrated with other harm reduction strategies. Services must be delivered in a woman-friendly format, as most harm-reduction interventions are designed for men [41, 49] . Women who inject drugs are often out of sight and out of mind, but with a growing number of vulnerable women injecting in Northeast India, strategies to reach and engage women in HIV and HCV prevention interventions are needed urgently.
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